Biomedical Systems Launches Next Generation eCOA Technology
Biomedical Systems, a premier global provider of centralized diagnostic services, launches its second generation clinical outcome assessment software offering three easy-to-use platforms to collect patient data.
Biomedical Systems, a global provider of centralized diagnostic services, launched its second generation clinical outcome assessment software offering three platforms to collect patient data: the home, investigative site and the web. In addition, the Android smartphone is part of the home technology and the Android tablet is used at the site. Biomedical Systems provides eCOA technology along with cardiac safety, pulmonary function and imaging centralized diagnostic services.
The second version eCOA technology, updating the first which launched in January 2013, now includes the following features:
- More flexible software
- Improved compliance
- Improved ease of use for both sites and patients
- More reliable data transmission
Read the full release here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
